476 related articles for article (PubMed ID: 34309158)
1. The addition of adjunctive letermovir to valganciclovir for refractory cytomegalovirus viremia in kidney transplant recipients.
Jorgenson MR; Descourouez JL; Garg N; Parajuli S; Mandelbrot DA; Odorico JS; Saddler CM; Smith JA
Transpl Infect Dis; 2021 Aug; 23(4):e13693. PubMed ID: 34309158
[TBL] [Abstract][Full Text] [Related]
2. Letermovir conversion after valganciclovir treatment in cytomegalovirus high-risk abdominal solid organ transplant recipients may promote development of cytomegalovirus-specific cell mediated immunity.
Jorgenson MR; Kleiboeker H; Garg N; Parajuli S; Mandelbrot DA; Odorico JS; Saddler CM; Smith JA
Transpl Infect Dis; 2022 Feb; 24(1):e13766. PubMed ID: 34799964
[TBL] [Abstract][Full Text] [Related]
3. Use of letermovir-valganciclovir combination as a step-down treatment after foscarnet for ganciclovir-resistant CMV infection in kidney transplant recipients.
Rho E; Näf B; Müller TF; Wüthrich RP; Schachter T; von Moos S
Clin Transplant; 2021 Nov; 35(11):e14401. PubMed ID: 34181768
[TBL] [Abstract][Full Text] [Related]
4. Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection.
Cherrier L; Nasar A; Goodlet KJ; Nailor MD; Tokman S; Chou S
Am J Transplant; 2018 Dec; 18(12):3060-3064. PubMed ID: 30286286
[TBL] [Abstract][Full Text] [Related]
5. Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial.
Limaye AP; Budde K; Humar A; Vincenti F; Kuypers DRJ; Carroll RP; Stauffer N; Murata Y; Strizki JM; Teal VL; Gilbert CL; Haber BA
JAMA; 2023 Jul; 330(1):33-42. PubMed ID: 37279999
[TBL] [Abstract][Full Text] [Related]
6. Letermovir prophylaxis in solid organ transplant-Assessing CMV breakthrough and tacrolimus drug interaction.
Winstead RJ; Kumar D; Brown A; Yakubu I; Song C; Thacker L; Gupta G
Transpl Infect Dis; 2021 Aug; 23(4):e13570. PubMed ID: 33469975
[TBL] [Abstract][Full Text] [Related]
7. Letermovir for cytomegalovirus prophylaxis in high-risk heart transplant recipients.
Golob S; Batra J; DeFilippis EM; Uriel M; Carey M; Gaine M; Mabasa A; Fried J; Raikelkar J; Restaino S; Hi Lee S; Latif F; Yuzefpolskaya M; Colombo PC; Choe J; Majure D; Jennings D; Pereira MR; Clerkin K; Sayer G; Uriel N
Clin Transplant; 2022 Dec; 36(12):e14808. PubMed ID: 36086937
[TBL] [Abstract][Full Text] [Related]
8. Letermovir treatment for CMV infection in kidney and pancreas transplantation: A valuable option for complicated cases.
Ortiz F; Lempinen M; Aaltonen S; Koivuviita N; Helanterä I
Clin Transplant; 2022 Feb; 36(2):e14537. PubMed ID: 34797574
[TBL] [Abstract][Full Text] [Related]
9. Successful Treatment of UL97 Mutation Ganciclovir-Resistant Cytomegalovirus Viremia in a Renal Transplant Recipient With Letermovir and Adjunct Hyperimmune Cytomegalovirus Immunoglobulin: A Case Report.
Pearston AP; Ingemi AI; Ripley K; Wilson TJ; Gruber J; McMahon M; Sutton S; Khardori N
Transplant Proc; 2021 May; 53(4):1284-1287. PubMed ID: 33715819
[TBL] [Abstract][Full Text] [Related]
10. Five-year single-center analysis of cytomegalovirus viremia in kidney transplant recipients and possible implication for novel prophylactic therapy approaches.
Trappe M; Affeldt P; Grundmann F; Kann M; Koehler FC; Müller RU; Stippel D; Kaiser R; Knops E; Heger E; Steger G; Klein F; Kurschat C; Di Cristanziano V
Transpl Infect Dis; 2024 Feb; 26(1):e14233. PubMed ID: 38180168
[TBL] [Abstract][Full Text] [Related]
11. Letermovir as Salvage Therapy for Cytomegalovirus Infection in Transplant Recipients.
Phoompoung P; Ferreira VH; Tikkanen J; Husain S; Viswabandya A; Kumar D; Humar A
Transplantation; 2020 Feb; 104(2):404-409. PubMed ID: 32000236
[TBL] [Abstract][Full Text] [Related]
12. A Case Report of Successful Use of Twice-Daily Letermovir in the Treatment of Resistant Cytomegalovirus in a Small Bowel Transplant Recipient.
Joharji H; Alaidaros F; Koujan H; Hamad A; Almaghrabi RS; Zidan A; Broering D; Al-Jedai A
Transplant Proc; 2022; 54(6):1679-1681. PubMed ID: 35842318
[TBL] [Abstract][Full Text] [Related]
13. Conversion from cytomegalovirus universal prophylaxis with valganciclovir to the preemptive monitoring approach to manage leukopenia after kidney or pancreas transplantation.
Jorgenson MR; Wong C; Descourouez JL; Saddler CM; Smith JA; Mandelbrot DA
Transpl Infect Dis; 2021 Aug; 23(4):e13617. PubMed ID: 33866643
[TBL] [Abstract][Full Text] [Related]
14. Single-center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients.
Aryal S; Katugaha SB; Cochrane A; Brown AW; Nathan SD; Shlobin OA; Ahmad K; Marinak L; Chun J; Fregoso M; Desai S; King C
Transpl Infect Dis; 2019 Dec; 21(6):e13166. PubMed ID: 31487755
[TBL] [Abstract][Full Text] [Related]
15. Real-life use of letermovir prophylaxis for cytomegalovirus in heart transplant recipients.
Saltiel G; Faure E; Assaf A; Chopin MC; Moreau F; Faure K; Goeminne C; Vuotto F
Clin Transplant; 2024 May; 38(5):e15327. PubMed ID: 38686437
[TBL] [Abstract][Full Text] [Related]
16. Preemptive treatment of Cytomegalovirus infection in kidney transplant recipients with letermovir: results of a Phase 2a study.
Stoelben S; Arns W; Renders L; Hummel J; Mühlfeld A; Stangl M; Fischereder M; Gwinner W; Suwelack B; Witzke O; Dürr M; Beelen DW; Michel D; Lischka P; Zimmermann H; Rübsamen-Schaeff H; Budde K
Transpl Int; 2014 Jan; 27(1):77-86. PubMed ID: 24164420
[TBL] [Abstract][Full Text] [Related]
17. Oral antiviral drugs for treatment of cytomegalovirus in transplant recipients.
Razonable RR
Clin Microbiol Infect; 2023 Sep; 29(9):1144-1149. PubMed ID: 36963566
[TBL] [Abstract][Full Text] [Related]
18. Emergence of letermovir resistance in solid organ transplant recipients with ganciclovir resistant cytomegalovirus infection: A case series and review of the literature.
Hofmann E; Sidler D; Dahdal S; Bittel P; Suter-Riniker F; Manuel O; Walti LN; Hirzel C
Transpl Infect Dis; 2021 Jun; 23(3):e13515. PubMed ID: 33210830
[TBL] [Abstract][Full Text] [Related]
19. Valacyclovir or valganciclovir for cytomegalovirus prophylaxis: A randomized controlled trial in adult and pediatric kidney transplant recipients.
Verghese PS; Evans MD; Hanson A; Hathi J; Chinnakotla S; Matas A; Balfour HH
J Clin Virol; 2024 Jun; 172():105678. PubMed ID: 38688164
[TBL] [Abstract][Full Text] [Related]
20. Letermovir in lung transplant recipients with cytomegalovirus infection: A retrospective observational study.
Veit T; Munker D; Barton J; Milger K; Kauke T; Meiser B; Michel S; Zoller M; Nitschko H; Keppler OT; Behr J; Kneidinger N
Am J Transplant; 2021 Oct; 21(10):3449-3455. PubMed ID: 34118118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
